April 20, 2018 Conference


A Review of New Glaucoma Drug Modalities in the Pipeline.

Dr. Husam Ansari, Ophthalmic Consultants of Boston (Presenter)

Non-adherence to medical treatment for glaucoma is notoriously prevalent and is linked to progression of the disease.  Among the barriers to adherence are difficulty with eye drop administration, side effects, forgetfulness, perceived life stress, and cost.  Numerous novel drug delivery systems for glaucoma are currently being developed and seek to remove several of these barriers by taking the task of medication adminsitration out of the hands of patients.  A comprehensive overview of the past, present, and future of sustained drug delivery for glaucoma and its perceived benefits will be presented.